Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Robert J. Padley"'
Autor:
Julie M. Parmentier, Jeff Voss, Candace Graff, Annette Schwartz, Maria Argiriadi, Michael Friedman, Heidi S. Camp, Robert J. Padley, Jonathan S. George, Deborah Hyland, Matthew Rosebraugh, Neil Wishart, Lisa Olson, Andrew J. Long
Publikováno v:
BMC Rheumatology, Vol 2, Iss 1, Pp 1-11 (2018)
Abstract Background Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumato
Externí odkaz:
https://doaj.org/article/74a65b57a23a4f92bcb3fbfd5e56a63c
Autor:
Ping Jiang, Roy Fleischmann, Alan Kivitz, Melanie Ruzek, Robert J. Padley, Feng Hong, Frank Wagner, Amit Khatri, Ahmed A. Othman, Heikki T. Mansikka, N. Khan
Publikováno v:
Arthritis & Rheumatology. 69:2283-2291
Objective Tumor necrosis factor (TNF) and interleukin-17 (IL-17) independently contribute to the pathophysiology of rheumatoid arthritis (RA). ABT-122 is a novel dual variable domain immunoglobulin that selectively and simultaneously targets human TN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7f916af56f5bf60a45b3a36dbab3f98
https://doi.org/10.1002/art.40319
https://doi.org/10.1002/art.40319
Autor:
Robert J. Padley, Ping Jiang, Armen Asatryan, Ahmed A. Othman, Heidi S. Camp, Mohamed-Eslam F. Mohamed
Publikováno v:
Clinical Pharmacokinetics. 55:1547-1558
ABT-494 is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders, with potential for an improved safety profile compared with non-selective JAK inhibitors. This work characterized the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a30c639613da084f15c7228b275dd744
https://doi.org/10.1007/s40262-016-0419-y
https://doi.org/10.1007/s40262-016-0419-y
Autor:
L. Olson, Robert J. Padley, Annette Schwartz, Matthew Rosebraugh, Deborah Hyland, Heidi S. Camp, Neil Wishart, Julie M. Parmentier, Candace Graff, Jonathan S. George, Maria A. Argiriadi, Jeff Voss, Michael M. Friedman, Andrew J. Long
Publikováno v:
BMC rheumatology
BMC Rheumatology, Vol 2, Iss 1, Pp 1-11 (2018)
BMC Rheumatology, Vol 2, Iss 1, Pp 1-11 (2018)
Background Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e6eed88fd36b22fdd8244c2f10d2ad7
https://pubmed.ncbi.nlm.nih.gov/30886973
https://pubmed.ncbi.nlm.nih.gov/30886973
Autor:
Robert J. Padley, Yihan Li, Paul M. Peloso, Jacob A. Aelion, N. Khan, Ahmed A. Othman, Amit Khatri, Mark C. Genovese, Heikki T. Mansikka, Kun Chen, Michael E. Weinblatt
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
Objective Tumor necrosis factor (TNF) and interleukin-17A (IL-17A) may independently contribute to the pathophysiology of rheumatoid arthritis (RA). This study sought to evaluate the safety and efficacy of ABT-122, a novel dual variable domain immuno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfe4dbd7366fbbf87f94e198222cbe2c
https://pubmed.ncbi.nlm.nih.gov/29855172
https://pubmed.ncbi.nlm.nih.gov/29855172
Autor:
Maria T. Vassileva, Jerome L. Fleg, Thomas S. Hatsukami, Daniel Isquith, Jie Sun, Gador Canton, Moni B. Neradilek, Robert J. Padley, Patrice Desvigne-Nickens, Yunjing Xue, Bradley T. Wyman, Daniel S. Hippe, Niranjan Balu, Michael Klimas, Kiyofumi Yamada, Chun Yuan, Xue Qiao Zhao
Publikováno v:
The International Journal of Cardiovascular Imaging. 31:95-103
This study sought to determine the multicenter reproducibility of magnetic resonance imaging (MRI) and the compatibility of different scanner platforms in assessing carotid plaque morphology and composition. A standardized multi-contrast MRI protocol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bf72f28f88d32153ad4c11b913ae808
https://doi.org/10.1007/s10554-014-0532-7
https://doi.org/10.1007/s10554-014-0532-7
Autor:
William J. Kostuk, Cathy A. Sila, Salvador Cruz-Flores, Robert J. Padley, Koon K. Teo, David C. Anderson, Shannon Grant, Larry B. Goldstein, Bernard R. Chaitman, William E. Boden, William S. Weintraub
Publikováno v:
Stroke. 44:2688-2693
Background and Purpose— In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with establi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::407a2cb74b2225addea79b646e75c021
https://doi.org/10.1161/strokeaha.113.001529
https://doi.org/10.1161/strokeaha.113.001529
Autor:
Milton, Packer, Wilson, Colucci, Lloyd, Fisher, Barry M, Massie, John R, Teerlink, James, Young, Robert J, Padley, Roopal, Thakkar, Leticia, Delgado-Herrera, Jeffrey, Salon, Chris, Garratt, Bidan, Huang, Toni, Sarapohja, Ross Randall, Zimmer
Publikováno v:
JACC: Heart Failure. 1:103-111
Background This study evaluated the efficacy and safety of levosimendan, a positive inotropic drug with vasodilator effects, given intravenously to patients with acutely decompensated heart failure (ADHF). Methods We performed 2 sequential trials, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a1fd2941fb19fe8db089d601589f9cf
https://doi.org/10.1016/j.jchf.2012.12.004
https://doi.org/10.1016/j.jchf.2012.12.004
Publikováno v:
Postgraduate Medicine. 123:70-83
Niacin is a water-soluble B vitamin (B3) known to have favorable effects on multiple lipid parameters, including raising high-density lipoprotein cholesterol (HDL-C) levels and lowering triglycerides (TGs), lipoprotein(a), and low-density lipoprotein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7799cfd8149fd00628869163d15729d
https://doi.org/10.3810/pgm.2011.03.2265
https://doi.org/10.3810/pgm.2011.03.2265
Publikováno v:
Journal of Clinical Lipidology. 3:109-118
Aggressive treatment of low-density lipoprotein cholesterol (LDL-C) fails to prevent most cardiovascular (CV) events. Concurrent treatment of LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) should be considered in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5977274205481f60d23cf27f331fdb5d
https://doi.org/10.1016/j.jacl.2009.02.009
https://doi.org/10.1016/j.jacl.2009.02.009